In vitro activity of eravacycline and mechanisms of resistance in enterococci
- 27 October 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 56 (6), 106215
- https://doi.org/10.1016/j.ijantimicag.2020.106215
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A Nosocomial Cluster of Tigecycline- and Vancomycin-Resistant Enterococcus faecium Isolates and the Impact of rpsJ and tet(M) Mutations on Tigecycline ResistanceMicrobial Drug Resistance, 2020
- Molecular basis for the emergence of a new hospital endemic tigecycline-resistant Enterococcus faecalis ST103 lineageInfection, Genetics and Evolution, 2018
- Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclatureDrug Resistance Updates, 2018
- Tetracycline Antibiotics and ResistanceCold Spring Harbor Perspectives in Medicine, 2016
- Review of Eravacycline, a Novel Fluorocycline Antibacterial AgentDrugs, 2016
- Genomic Analysis of Reduced Susceptibility to Tigecycline in Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 2015
- Antibiotic resistance inEnterococcus faeciumclinical isolatesExpert Review of Anti-infective Therapy, 2013
- Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline AntibioticAntimicrobial Agents and Chemotherapy, 2012
- Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral EfficacyJournal of Medicinal Chemistry, 2012
- The tetracycline resistomeCellular and Molecular Life Sciences, 2009